Evidence map›Paper›PMID 22508938›Full record

ArticleBlood2012

Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2.

Pradeep Sathyanarayana, Arvind Dev, Anamika Pradeep, Melanie Ufkin, Jonathan D Licht, Don M Wojchowski

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Mouse Models of Erythropoiesis and Associated Diseases.Methods in molecular biology (Clifton, N.J.) · 2018
    Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Pradeep SathyanarayanaStem and Progenitor Cell Biology Program, Maine Medical Center Research Institute, Scarborough, ME, USA.
Arvind Dev
Anamika Pradeep
Melanie Ufkin
Jonathan D Licht
Don M Wojchowski
Maine Medical Center · USMaine Medical Center Research Institute · USNorthwestern University · US

Funding

Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI CHRISTOPHER S FRANCKLYN · 2012 to 2026
$58.4M
Transcriptional Decisions in Endothelial Cell DifferentiationP20RR015555 · NCRR · MAINE MEDICAL CENTER · PI PRUDOVSKY, IGOR · 2000 to 2009
$21.4M
WNT SIGNALING IN PREIMPLANTATION EMBRYOP20RR018789 · NCRR · MAINE MEDICAL CENTER · PI WANG, ZACK Z. · 2003 to 2011
$18.9M
Phase III COBRE in Vascular BiologyP30GM103392 · NIGMS · MAINEHEALTH · PI ST. GERMAIN, DONALD L. · 2012 to 2016
$4.7M
TRANSCRIPTIONAL REPRESSION BY THE WTI PROTEINR01CA059998 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LICHT, JONATHAN D. · 1994 to 2010
$3.3M
Novel regulators of stress erythropoiesisR01DK089439 · NIDDK · UNIVERSITY OF NEW HAMPSHIRE · PI WOJCHOWSKI, DON MICHAEL · 2010 to 2017
$2.0M
COBRE in Stem Cell Biology and Regenerative MedicineP20GM103465 · NIGMS · MAINEHEALTH · PI WOJCHOWSKI, DON MICHAEL · 2012 to 2012
$2.0M
NCI NIH HHS R01 CA059998NCI NIH HHS R01CA059998NCRR NIH HHS P20 RR015555NCRR NIH HHS P20RR015555NCRR NIH HHS P20 RR018789NCRR NIH HHS P20RR18789NIDDK NIH HHS R01 DK089439NIDDK NIH HHS R01DK089439NIGMS NIH HHS 8P20GM103449NIGMS NIH HHS 8P20GM103465NIGMS NIH HHS 8P30GM103392NIGMS NIH HHS P20 GM103449NIGMS NIH HHS P20 GM103465NIGMS NIH HHS P30 GM103392
6 · The paper itself

Abstract

Sprouty proteins are established modifiers of receptor tyrosine kinase (RTK) signaling and play important roles in vasculogenesis, bone morphogenesis, and renal uteric branching. Little is understood, however, concerning possible roles for these molecular adaptors during hematopoiesis. Within erythroid lineage, Spry1 was observed to be selectively and highly expressed at CFU-e to erythroblast stages. In analyses of possible functional roles, an Mx1-Cre approach was applied to conditionally delete Spry1. At steady state, Spry1 deletion selectively perturbed erythroid development and led to reticulocytosis plus heightened splenic erythropoiesis. When challenged by hemolysis, Spry1-null mice exhibited worsened anemia and delayed recovery. During short-term marrow transplantation, Spry1-null donor marrow also failed to efficiently rescue the erythron. In each anemia model, however, hyperexpansion of erythroid progenitors was observed. Spry function depends on phosphorylation of a conserved N-terminal PY motif. Through an LC-MS/MS approach, Spry1 was discovered to be regulated via the erythropoietin receptor (EPOR), with marked EPO-induced Spry1-PY53 phosphorylation observed. When EPOR signaling pathways were analyzed within Spry1-deficient erythroid progenitors, hyperactivation of not only Erk1,2 but also Jak2 was observed. Studies implicate Spry1 as a novel regulator of erythropoiesis during anemia, transducer of EPOR signals, and candidate suppressor of Jak2 activity.

Indexed as

ErythropoiesisAdaptor Proteins, Signal TransducingAnemiaAnimalsBone Marrow TransplantationCells, CulturedEnzyme ActivationErythroblastsErythropoietinGene DeletionGene Expression Regulation, DevelopmentalJanus Kinase 2Membrane ProteinsMiceMice, Inbred C57BLMitogen-Activated Protein Kinase 1Adaptor Proteins, Signal TransducingErythropoietinJanus Kinase 2Membrane ProteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PhosphoproteinsReceptors, ErythropoietinSpry1 protein, mouse

Identifiers

PMID22508938
PMCPMC3369686
OpenAlexW2066225693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.